This activity is intended for hematologists, hematologists/oncologists, medical oncologists, nurses, physician assistants, and nurse practitioners caring for patients with blood cancers.

Genomic profiling is widely recognized as a key way to identify strategies for treating hematologic (and other) cancers. However, there is a significant disconnect between scientific evidence and hematologist/oncologist knowledge, confidence, and practice. As a wealth of new information continues to emerge, it is essential that hematologists/oncologists have a strong foundational understanding of genomics and its practical applications.

• Review genomic principles, terminology, technologies, and applications
• Describe available genomic tests for diagnosis of hematologic malignancies and relevant premalignant conditions
• Interpret test results and select appropriate therapeutic agents to manage specific hematologic malignancies
• Develop strategies to explain tests and their implications to patients and caregivers

PLANNING COMMITTEE

Jennifer Brown, MD, PhD (Planning Committee Chair)
Director, CLL Center of the Division of Hematologic Malignancies
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Rafael Fonseca, MD
Director, Mayo Clinic Comprehensive Cancer Center
Director for Innovation and Transformational Relationships
Getz Family Professor of Cancer, Distinguished Mayo Investigator
Phoenix, AZ

Neha Mehta-Shah, MD, MSCI
Assistant Professor, Department of Medicine
Division of Medical Oncology
Washington University in St. Louis School of Medicine
St. Louis, MO

Alice Mims, MD
Acute Leukemia Clinical Research Director
Assistant Professor, Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, OH

Nina Fragale, NP
Internal Medicine, Medical Oncology
Washington University in St. Louis School of Medicine
St. Louis, MO

FACULTY

Mary Albrethsen, APRN-CNP
Nurse Practitioner
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, OH

Rafael Fonseca, MD
Director, Mayo Clinic Comprehensive Cancer Center
Director for Innovation and Transformational Relationships
Getz Family Professor of Cancer, Distinguished Mayo Investigator
Phoenix, AZ

Ann S. LaCasce, MD, MMSc
Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
Fellowship Program in Hematology/Oncology Chair
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Robert Coleman Lindsley, Jr., MD, PhD
Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Neha Mehta-Shah, MD, MSCI
Assistant Professor, Department of Medicine
Division of Medical Oncology
Washington University in St. Louis School of Medicine
St. Louis, MO

Alice Mims, MD
Acute Leukemia Clinical Research Director
Assistant Professor, Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, OH

Darci L. Zblewski, APRN, CNP
Nurse Practitioner
Mayo Clinic
Rochester, MN

PHYSICIAN ACCREDITED PROVIDER
This physician activity is provided by The American Society of Hematology.

 
ACCREDITATION STATEMENT
The American Society of Hematology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

The American Society Hematology (ASH) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

NURSING ACCREDITED PROVIDER
This nurse activity is provided by The Leukemia & Lymphoma Society.

Nurses
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0–1.5 continuing education contact hour(s) through the California Board of Registered Nursing.

Nurse Practitioners
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hour(s) of pharmacology) by the American Association of Nurse Practitioners^®. Activity ID# 24016477. This activity was planned in accordance with AANP Accreditation Standards and Policies.

All other healthcare professionals completing this course will be issued a statement of participation.

TFF, ASH, and LLS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ASH, and LLS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by educational grants from AbbVie, Astellas, Daiichi Sankyo, Illumina, and Pharmacyclics.

The American Society of Hematology, The Leukemia & Lymphoma Society, and The France Foundation present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ASH, LLS, TFF, and the commercial supporter(s) assume no liability for the information herein.

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission.